Blog — Clinical Pathways

Now Available! ICH E6(R3) Comparison Tool. Includes Final Principles, Annex 1, and draft Annex 2. Click here to purchase.

draft guidance

New Draft Guidance on Protocol Deviation Management Part 2/2

New Draft Guidance on Protocol Deviation Management Part 2/2

01/21/2025

-

The guidance breaks down the roles and responsibilities of the investigator, sponsor, and Institutional Review Board (IRB) in regards to monitoring, mitigating, reporting, and evaluating protocol deviations (PDs). The investigator, who is responsible for the conduct of the trial and protection of the rights, safety, and welfare of the participants must report all PDs to the sponsor, highlighting the important PDs.

New Draft Guidance on Predetermined Change Control Plans for Medical Devices

New Draft Guidance on Predetermined Change Control Plans for Medical Devices

09/18/2024

-

A new draft guidance for industry was released on August 22, 2024 by the US Food and Drug Administration (FDA) on Predetermined Change Control Plans (PCCP) for Medical Devices. The draft guidance provides an in-depth history of the origins of PCCPs and how the concept of device changes not requiring new 510(k) submissions has already made in an appearance in other FDA guidances.

FDA Releases Draft Guidance on Improving Enrollment of Participants from Underrepresented Populations

07/11/2024

-

On June 26, 2024, the US Food and Drug Administration (FDA) released a new draft guidance “Diversity Action Plan to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.” The underrepresented populations in clinical trials can be disaggregated by sex, age, and racial and ethnic demographics. If a subset of a population is not present during the clinical studies, potential differences in safety information may not be fully understood.

FDA Releases New Draft Guidance on Data Integrity for In Vivo Bioavailability and Bioequivalence Studies

07/05/2024

-

In April 2024, the US Food and Drug Administration (FDA) released a draft guidance for industry titled: Data Integrity for In Vivo Bioavailability and Bioequivalence Studies. The draft guidance explains the difference between data quality and data integrity. While both are necessary to maintain in a clinical study in order to obtain reputable data, they each have important differences.

FDA publishes Draft Guidance for Industry: Processes and Practices Applicable to BIMO Inspections

06/18/2024

-

On June 5th 2024, the US Food and Drug Administration (FDA) released a draft guidance for industry on the processes and practices that apply during an FDA Bioresearch Monitoring (BIMO) inspection in compliance with section 3612(b)(2) of the Food and Drug Omnibus Reform Act of 2022 (FDORA).